Nephros Earnings Call Highlights Growth Amid Tariffs

Nephros, Inc. ((NEPH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Nephros, Inc. delivered an upbeat earnings call that balanced strong full‑year growth with transparency about late‑year margin pressure. Management highlighted a 33% jump in revenue, a return to meaningful profitability, and solid cash generation, while acknowledging that tariffs and higher spending weighed on fourth‑quarter margins and earnings.

Revenue Surges on Programmatic Demand

Nephros reported full‑year 2025 revenue of $18.8 million, up 33% from $14.2 million in 2024, underscoring robust demand for its water‑focused solutions. Fourth‑quarter sales climbed 22% to $4.7 million, fueled by stronger programmatic reorders and an expanding base of active customer sites.

Profits Rebound for Second Straight Year

The company posted approximately $1.2 million in net income for 2025, a sharp improvement from $0.1 million a year earlier and its second consecutive profitable year. Management framed this as evidence that the business model is scaling, even as it continues to invest for growth.

EBITDA Strength and Positive Cash Generation

Adjusted EBITDA nearly tripled to $1.6 million in 2025 from $0.548 million in 2024, reflecting better operating leverage over the full year. Operating cash flow also turned a corner, with $1.6 million of net cash provided by operations versus roughly $0.5 million used in the prior year.

Expanding, Sticky Customer Base Drives Visibility

Active customer sites rose to about 1,681 from roughly 1,500 at the end of 2024, an increase of around 12%. Management noted that programmatic sales accounted for more than 90% of revenue, supporting recurring revenue visibility and reinforcing the stickiness of its installed base.

Balance Sheet Remains Strong and Debt‑Free

Nephros ended 2025 with $5.4 million in cash, up from $3.8 million a year earlier, providing a healthy liquidity cushion. The company remains debt‑free, giving it flexibility to fund growth initiatives and absorb near‑term cost pressures without resorting to leverage.

Broader Product, Service and Education Push

The company broadened its offerings into applications such as ice machines, drinking fountains, bottle fillers, and sterile processing, aiming to widen its addressable market. It also rolled out service programs for installation and replacement, and launched the Nephros Water Institute, which has already educated more than 1,000 participants to support long‑term demand.

Q4 Margin Compression Tempers the Upside

Despite flat full‑year gross margin at 62%, fourth‑quarter gross margin slipped to 58% from 64% in the prior‑year quarter. The decline reflected higher input costs and tariffs, illustrating that the company’s growth trajectory is not immune to external pressures on profitability.

Tariffs Create Cost Headwinds and Policy Risk

Management pointed to a 15% tariff on goods imported from Italy, implemented in April 2025 and later reduced to 10% in early 2026, as a key driver of margin erosion. They also emphasized uncertainty around U.S. tariff policy, which could continue to impact costs and pricing decisions.

Stepped‑Up Spending in R&D and SG&A

Research and development spending rose about 44% to $1.3 million in 2025, with fourth‑quarter R&D at $0.4 million versus $0.3 million a year earlier, reflecting investment in innovation. SG&A climbed to $9.0 million from $7.7 million, including roughly 24% growth in Q4 tied to bonuses, commissions, and one‑time product and market analysis costs.

Soft Q4 Earnings and EBITDA Despite Growth

Fourth‑quarter 2025 net income slipped to roughly $0.1 million from $0.3 million a year prior, a decline of about 67%, as higher costs outpaced revenue gains. Q4 adjusted EBITDA fell to $131,000 from $481,000, underscoring the impact of margin compression and elevated operating expenses late in the year.

Working Capital Needs Rise as Business Scales

Operating cash flow in 2025 reflected a build in accounts receivable of about $0.6 million and inventory of roughly $0.7 million, which absorbed cash. These working capital demands highlight the financial requirements of supporting a growing revenue base and could create near‑term cash pressure if not carefully managed.

Concentration Risk in Programmatic Revenue

While programmatic revenue above 90% offers strong recurring visibility, it also concentrates the business around a single revenue pattern. Management acknowledged that a still‑developing non‑healthcare commercial pipeline leaves the company exposed if reorder rates weaken or site growth slows.

Outlook: Multi‑Year Growth with Cost Watchpoints

Looking to 2026, Nephros framed its strategy as a multi‑year growth story built on products, services, and education, with continued focus on expanding recurring programmatic revenue as active sites rise. Management’s confidence is underpinned by 2025’s 33% revenue growth, solid profitability, and strong balance sheet, even as they monitor tariffs and elevated R&D and SG&A spending.

Nephros’ latest call painted a picture of a company successfully scaling its recurring revenue model while confronting the realities of tariffs and higher operating costs. For investors, the key takeaway is a business delivering robust growth and positive cash flow, but one that must carefully manage margins and revenue concentration as it pursues its next leg of expansion.